Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERDICT trial in active ulcerative colitis
NL-OMON51131Phase 4Recruiting
- Sponsor
- Alimentiv Inc.
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vedolizumab in autoimmune colitis and inflammatory bowel disease (IBD) (3 arms), sponsored by Alimentiv Inc. Primary endpoint: Time to ulcerative-colitis-related complication in achieved-target population. Started Jul 2021; status: recruiting.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON51131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51131.